Table 3 Univariate analysis of prognostic factors for stage III undifferentiated gastric adenocarcinoma

Age (years)

0.200

 ≤65 (n = 449)

23.8

20.4–27.3

39.2

29.2

 >65 (n = 385)

21.8

19.0–24.6

33.5

24.1

Sex

0.374

 Male (n = 474)

21.8

19.1–24.6

34.7

25.8

 Female (n = 360)

25.2

21.3–29.2

38.3

28.6

Tumor size (cm)

0.223

 ≤5 (n = 410)

28.4

23.9–33.0

43.1

32.9

 >5 (n = 420)

19.0

16.6–21.4

29.2

21.6

Type of gastrectomy

<0.0001

 Total (n = 308)

17.8

15.0–20.7

29.6

20.6

 Subtotal (n = 526)

26.6

23.1–30.1

40.1

30.7

Extent of LN dissection

0.834

 <D2 (n = 246)

24.3

19.6–28.9

36.2

27.3

 ≥D2 (n = 588)

22.2

19.3–25.2

36.2

26.9

T status

0.817

 T1/T2 (n = 17)

17.6

5.6–9.6

41.2

32.9

 T3/T4 (n = 817)

23.0

20.5–25.6

36.2

26.9

LN ratio

<0.0001

 ≤0.34 (n = 416)

38.7

30.8–46.7

52.4

41.9

 >0.34 (n = 418)

15.8

13.5–18.1

20.1

12.0

N status

<0.0001

 N0 (n = 15)

NA

57.8

57.8

 N1 (n = 129)

65.3

29.5–101.1

58.9

50.3

 N2 (n = 188)

28.6

20.1–37.1

44.3

33.8

 N3 (n = 52)

18.8

16.7–0.9

26.5

17.3

Histology type

0.038

 MC (n = 37)

47.8

0.0–103.0

51.1

48.1

 SRCC (n = 248)

20.8

16.5–25.0

36.9

26.0

 PDC (n = 549)

22.3

19.5–25.1

34.9

26.1

Resection margins

<0.0001

 R0 (n = 709)

25.4

22.4–28.3

39.8

30.1

 R1 (n = 125)

15.8

12.7–18.9

15.3

8.6

Lymphatic invasion

0.006

 No (n = 125)

33.1

23.4–42.8

45.6

36.0

 Yes (n = 698)

21.5

19.5–23.6

34.1

25.0

Vascular invasion

0.024

 No (n = 635)

24.3

21.7–26.9

37.2

28.1

 Yes (n = 185)

18.5

14.7–22.2

31.7

23.2

Perineural invasion

<0.0001

 No (n = 234)

31.4

19.1–43.8

46.9

40.4

 Yes (n = 582)

20.8

18.7–22.9

31.2

21.0

Chemotherapy

<0.001

 No (n = 179)

16.0

11.3–20.6

29.1

20.3

 Yes (n = 655)

24.5

22.0–27.0

38.1

28.7